Integrated bioanalytical strategy for LNP-mRNA products
Tuesday 15 October 2024
07:00 [PDT] 10:00 [EDT] 15:00 [BST]
Alternative time zones
Unlocking the potential of LNP-mRNA: bioanalytical insights for next-generation therapeutics. The development of LNP-mRNA-based preventative and therapeutic products has gained significant attention following the approval of the first new modality during the COVID-19 pandemic. The LNP-mRNA modality has opened a new and promising direction for pharmaceutical R&D, providing alternative and effective therapeutic strategies. However, the biochemical characteristics of LNP-mRNA pose significant challenges for bioanalysis. To support mRNA drug development, we share some bioanalytical strategies tailored to this novel drug and modality.
What will you learn?
- Strategies for bioanalysis of LNP-mRNA products
- The biochemical challenges posed by LNP-mRNA
Who this may interest?
- Bioanalytical scientists, especially in the pharmaceutical industry
- Sponsors who have therapeutic products as part of their pipelines
Nan Jia
Assistant Director
WuXi AppTec (Shanghai, China)
Dr Jia currently serves as the Assistant Director of the Immunology Lab in the Bioanalysis Department of WuXi AppTec, focusing on leveraging bioanalytical technologies to aid drug research and development. Jia received a PhD degree in Biochemistry from Imperial College London (UK). Before joining WuXi AppTec, he worked as a Post-Doctoral Researcher at Beth Israel Deaconess Medical Center (Harvard Medical School; MA, USA), with his primary research focus on the bioanalysis of carbohydrates. Jia has authored 11 peer-reviewed publications.
In association with
